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There are few published data on long‑term treatment with sirolimus in lymphangioleiomyomatosis 
(LAM). The objective of this study was to describe the long‑term effect of sirolimus in a series of LAM 
patients followed up in a referral centre, focusing on pulmonary function. We retrospectively reviewed 
a series of 48 patients with LAM diagnosed, followed up and treated with sirolimus in a single centre. 
Response to sirolimus was evaluated at 1 and 5 years. A negative sirolimus response was defined as an 
 FEV1 decline greater than − 75 ml/year. A mixed‑effects model was used to estimate the longitudinal 
changes in  FEV1 (average slope), both as absolute (ml/year) and as predicted values (%predicted/year). 
From a total of 48 patients, 9 patients underwent lung transplantation and 4 died during the study. 
Mean (95% CI)  FEV1 slope over 5 years was − 0.14 (− 26.13 to 25.85) ml/year in the whole LAM group, 
42.55 (14.87 to 70.22) ml/year in the responder group, − 54.00 (− 71.60 to − 36.39) ml/year in the partial 
responder group and − 84.19 (− 113.5 to − 54.0) ml/year in the non‑responder group. After 5 years of 
sirolimus treatment 59% had a positive response, 30% had a partial response and 11% had a negative 
response. Our study found that sirolimus treatment had a positive long‑term effect on most LAM 
patients.
Lymphangioleiomyomatosis (LAM) is a rare, slowly progressive disease characterized by the proliferation of 
abnormal smooth muscle-like cells named LAM  cells1. This cell proliferation is associated with cystic lung dis-
ease, chylous fluid accumulations and abdominal angiomyolipomas and  lymphangioleiomyomas2. LAM affects 
almost exclusively adult women and occurs sporadically (S-LAM) or in association with the tuberous sclerosis 
complex (TSC-LAM). TSC-LAM is caused by mutations in two tumour suppressor genes: TSC1 and TSC2, with 
consequent loss of function of hamartin and tuberin proteins,  respectively3,4. S-LAM, by contrast, is not heredi-
tary. Recently, a genome-wide association study was performed and the data suggested that NR2F2 expression 
may have a role in S-LAM5.
In recent years, mTOR inhibitors have emerged as a therapeutic option for LAM. Before 2011, multiple 
non-evidence-based medical treatments were described, such as hormonal manipulation, oophorectomy or 
 tamoxifen6,7, and most eligible LAM patients who developed respiratory failure were referred for lung transplant 
(LT). After 2011, with the publication of the Multicentre International LAM Efficacy of Sirolimus (MILES)  trial8 
and its approval by the Food and Drug Administration in 2015, sirolimus was introduced as the first effective 
treatment in these patients. However, long-term results of sirolimus treatment are  scarce9.
Our institution developed the first lung transplant program in Spain in 1990. The programme receives national 
patient referrals with LAM: this provided an impetus to adopt the most recent advances in LAM treatment. 
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Sirolimus was introduced, as an off-label use, in LAM patients in November 2007 following the publication of 
the first trial in renal  angiomyolipomas10. The objective of the present study was to review the long-term effect 
of sirolimus in a series of LAM patients followed up in a referral centre, focusing on pulmonary function.
Patients and clinical assesment
The study retrospectively included all patients with LAM diagnosed, treated with sirolimus and followed up in a 
tertiary referral centre from January 1990 to January 2020. Data compiled included clinical findings, diagnostic 
methods, treatment, lung function, presence of tuberous sclerosis and extrapulmonary involvement such as renal 
angiomyolipoma, pleural or abdominal complications. The Ethics Committee of the Vall d’Hebron University 
Hospital (Barcelona, Spain BSG-SIR-2019–01) approved the study. Informed consent was waived due to retro-
spective nature of the study by The Ethics Committee of the Vall d’Hebron University Hospital. All methods in 
this study were performed in accordance with the relevant guidelines and regulations.
Pulmonary function tests were performed according to European Respiratory Society  guidelines11. All  FEV1 
values in our study were obtain without bronchodilators. Patients with LAM underwent spirometric variables and 
diffusing capacity -at baseline, 1 year, 2 years, 3 years, 4 years and 5 years. Thoracic and abdominal CT scan were 
performed in all patients. Lung biopsy was performed only in patients with exclusive pulmonary involvement; 
biopsy was generally avoided if patients had lung cysts associated with renal angiomyolipomas.
Time to event was calculated as the number of years between sirolimus initiation to the date of lung trans-
plantation or date of death, whichever came first.
Patients were classified into two cohorts according to the availability of sirolimus at diagnosis: a historical 
sirolimus cohort (HSC) of patients for whom sirolimus was not available at diagnosis but who received the drug 
after 2007 and a contemporary cohort (CC), in whom sirolimus was started immediately after the diagnosis.
Sirolimus treatment. From November 2007, sirolimus was indicated in the case of  FEV1 < 80%, angiomy-
olipoma bigger than 4 cm of diameter or multiple angiomyolipomas. Sirolimus was prescribed at a dose between 
1 and 4 mg once daily adjusted to obtain target trough blood levels between 5 and 15 ng/ml measured with liquid 
chromatography-mass spectrometry. Adverse effects and drug interactions were also recorded.
We defined the sirolimus response based on the rate of  FEV1 decline in LAM patients without specific treat-
ment, which has been reported as − 75 ml/year12. Age-related physiological decline in healthy adults under 
60 years old has been reported to be around − 20 ml/year13–15. Consequently, improvement, stabilization or loss 
of  FEV1 similar to the physiological decline was considered a positive response to sirolimus. Patients who had 
an  FEV1 decline rate between − 20 and − 75 ml/year were considered partial responders. Non-responders had 
an  FEV1 decline greater than − 75 ml/year. Sirolimus response was assessed at 1 year and long-term response at 
5 years. Patients who underwent LT before completing 1 or 5 years of sirolimus treatment were not included in 
the respective analysis.
Angiomyolipomas’ shrinkage rate was calculated as the change in maximum diameter after 1 year of siroli-
mus treatment. Patients with a decrease or stabilization in angiomyolipoma size were considered responders.
Statistical analysis. Mixed-effect models were used to estimate the longitudinal changes in  FEV1 (aver-
age slope), both as absolute (ml/year) and as predicted values (%predicted/year). In these analyses, time was 
entered as a random effect. We then categorised individuals into three groups: (1) responders (if the individual-
ised estimate was less than − 20 ml/year), (2) partial responders (if the individualised estimate was between − 20 
and − 75 ml/year); and (3) non-responders (if the individualised estimate was greater than − 75 ml/year). Quali-
tative data are expressed as frequencies and percentages. Normally-distributed quantitative data are expressed 
as mean ± SD; non-normally-distributed data are expressed as median and interquartile range (IQR). The demo-
graphic and clinical characteristics of the HSC and CC were compared using ANOVA or chi-square test, as 
appropriate. Pulmonary function tests (PFT) of non-responders, partial responders and responders to siroli-
mus were compared using the Mann Whitney test. Time from sirolimus initiation to death/transplantation was 
assessed using Kaplan–Meier curves. Cox regression analysis was used to compared HSC and CC. The 95% CI 
was obtained from the mean estimates. A p-value < 0.05 was considered statistically significant. Data were ana-
lysed using STATA version 14 (StataCorp, College Station, TX, USA) and SPSS version 27 (IBM Corp., Armonk, 
NY, USA).
Results
Forty-eight LAM patients diagnosed and followed-up in our outpatient clinic and treated with sirolimus were 
recruited: 19 (40%) patients correspond to HSC and 29 (60%) to CC. Four (8.3%) of them had LAM associ-
ated with TSC. The median age at onset of symptoms and at diagnosis was 36 (30–44) and 38 (34–46) years, 
respectively. Thirty-nine (81%) patients were pre-menopausal at diagnosis and 9 (19%) were post-menopausal. 
Three (6%) patients were smokers at diagnosis and 14 (29%) were ex-smokers. Dyspnoea was the most com-
mon presenting symptom in 17 (35%) patients followed by pneumothorax in 15 (31%) patients. Mean  FEV1 at 
diagnosis was 68 ± 26% of the predicted. On thoracic CT, all patients had multiple cystic images with bilateral 
distribution, predominantly in the middle and lower lobes. The method of diagnosis was surgical lung biopsy 
in 28 (58%) patients, clinicoradiological findings in 12 (25%) and transbronchial cryobiopsy in 8 (17%). Three 
(6%) diagnoses were incidental in asymptomatic patients.
The mean duration of follow-up was 11.7 ± 6.9 years from diagnosis and mean time of sirolimus treatment 
was 5.6 ± 3.5 years. During follow-up, the most common pleural complications were pneumothorax, which 
occurred in 8 (17%) patients, chylous effusion in 4 (8%), and transudative pleural effusion in 3 (6%). Nineteen 
(40%) patients needed chemical pleurodesis and 2 (4%) needed thoracic duct ligation. Twenty (42%) patients 
3
Vol.:(0123456789)
Scientific Reports |        (2021) 11:10171  | https://doi.org/10.1038/s41598-021-89562-0
www.nature.com/scientificreports/
had renal angiomyolipoma; 2 of them required embolization and 2 underwent surgery. Other extrapulmonary 
complications included 5 (10%) cases of abdominal lymphangioleiomyomas.
From the study cohort of 48 patients, 9 (19%) patients underwent lung transplantation (LT). These patients 
were treated with sirolimus before the LT for a median time of 18 (7–42) months. Pre-sirolimus spirometry 
demonstrated severe obstruction: mean FVC was 47 ± 15% pred.,  FEV1 was 26 ± 9% pred. and  FEV1/FVC ratio 
was 45 ± 11%. Pre-LT spirometry showed a mean FVC of 44 ± 18%,  FEV1 of 30 ± 15% and  FEV1/FVC ratio of 
43 ± 10%. After LT, patients received tacrolimus, mycophenolate mofetil and steroids as immunosuppression 
according to the lung transplant unit protocol.
During the study period, 4 (8%) patients died, only one of them had received LT and died from an acute 
cellular rejection. The other causes of death were respiratory failure, renal failure and cholangiocarcinoma. A 
comparison between the HSC and CC is presented in Table 1.
Survival rates free from death and/or transplantation at 1- and 5-years after sirolimus initiation were 87% 
and 73% respectively (Fig. 1).
HSC patients presented a significantly higher long-term risk of death and/or LT compared to CC (Fig. 2).
Sirolimus treatment. From November 2007, 48 patients with LAM were treated at our hospital with siroli-
mus. Twenty-eight (58%) patients initiated sirolimus because of  FEV1 < 80%, 4 (8%) because of AML and 16 
(33%) because of both. Mean sirolimus dose was 2.2 ± 0.8 mg and mean blood trough levels were 7.5 ± 2.7 ng/ml.
Table 1.  Comparison between historical sirolimus cohort (sirolimus not available at diagnosis) and 
contemporary cohort. IQR interquartile range, SD standard deviation, PFT pulmonary function test, TSC 
tuberous sclerosis complex, AML angiomyolipoma, LT lung transplantation.
Historical sirolimus cohort n = 19 Contemporary cohort n = 29 p-value
Age at diagnosis (years), median (IQR) 35 (29–38) 43 (36–46) 0.014
Initial symptom, n (%) 0.773
Dyspnoea 7 (37) 10 (34)
Pneumothorax 7 (37) 8 (28)
Haemoptysis 2 (11) 2 (7)
Chylothorax 1 (5) 4 (14)
Asymptomatic 1 (5) 2 (7)
Cough 0 (0) 1 (3)
Abdominal pain 0 (0) 2 (7)
Pleuritic chest pain 1 (5) 0 (0)
Diagnostic method, n (%) 0.042
Surgical lung biopsy 13 (68) 15 (52)
Clinicoradiological 6 (32) 6 (21)
Transbronchial cryobiopsy 0 (0) 8 (28)
PFT at diagnosis, mean (SD) median (IQR)
FVC, ml 2651 (1037)2890 (1820–3130)
3063 (841)
3070 (2320–3850) 0.137


















Suppl. oxygen use, n (%) 8 (42) 4 (14) 0.027
Associated TSC, n (%) 3 (16) 1 (3) 0.130
AML, n (%) 12 (63) 8 (28) 0.015
Pneumothorax during follow-up 0.025
Number pneumothorax/n patients 21/6 2/2
Chylothorax during follow-up 0.130
Number chylothorax/n patients 4/3 1/1
Chemical pleurodesis 11 (58) 8 (28) 0.044
Thoracic duct ligation 0 (0) 2 (7) 0.242
Follow-up (years), median (IQR) 17 (14–22) 8 (5–10)  < 0.001
LT, n (%) 8 (42) 1 (3)  < 0.001
Death, n (%) 3 (16) 1 (3) 0.130
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Of note, only one patient from the HSC developed pneumothorax under sirolimus treatment, while the others 
developed this complication before they started treatment. No patients developed chylothorax under sirolimus 
treatment (1 patient from the CC experienced the complication before initiating treatment).
In the HSC, the median time between onset of symptoms and starting sirolimus was 12 (4–15) years. In the 
CC, the median time from the onset of symptoms to starting sirolimus was 1 (0–3) years. The mean spirom-
etry values before sirolimus in the HSC and CC were: FVC 62 ± 25% pred. versus 84 ± 21% pred respectively 
(p = 0.002),  FEV1 41 ± 21% pred. versus 74 ± 22% pred. (p < 0.001),  DLCO 40 ± 22% versus 55 ± 17% (p = 0.228).
Safety. Side effects were recorded in 16 (33%) patients and tended to occur shortly after starting treatment and 
decrease over time. The most common side effect was oral aphthous ulcers in 8 (17%), ovarian cysts in 3 (6%), 
severe increase in serum cholesterol in 2 (4%), liver enzyme abnormalities in 2 (4%), anasarca in 1 (2%) and leg 
Figure 1.  Kaplan–Meier survival curve free from death/transplantation from the time of sirolimus initiation. 
Mean time of sirolimus treatment was 5.6 ± 3.5 years.
Figure 2.  Kaplan Meier survival curve free from death/transplantation from the time of sirolimus initiation. 
HSC (blue) and CC (green).
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swelling in 1 (2%). Only 1 patient discontinued sirolimus treatment due to fluid retention and in 3 cases siroli-
mus was temporarily withdrawn due to oral aphthous ulcers.
Efficacy. At the end of the study, of 48 sirolimus-treated patients, 38 (79%) had had treatment for 1 year and 27 
(56%) had had a minimum of 5 years’ treatment (Fig. 3).
After 1 year, a positive response to sirolimus was observed in 23 (60%) patients and a partial response in 11 
(29%) (Fig. 3). Long-term efficacy of sirolimus was studied in 27 patients who had received 5 years or more of 
sirolimus treatment: 59% were responders, 30% were partial responders and 11% non-responders. There were 
no differences in FVC,  FEV1 or  DLCO at diagnosis or before sirolimus treatment between responders, partial 
responders and non-responders; see Table 2. However, significantly differences were observed in  FEV1 after 
5-years of sirolimus treatment having non-responders lower values.
Of note, from the responders group, four patients developed chylothorax and only one patient was treated by 
pleurodesis before sirolimus was initiated. In the other 3 patients, sirolimus was started due to the chylothorax.
Mean (95% CI)  FEV1 slope over 5 years was − 0.14 (− 26.13 to 25.85) ml/year in the whole LAM group, 42.55 
(14.87 to 70.22) ml/year in the responder group, − 54.00 (− 71.60 to − 36.39) ml/year in the partial responder 
group and − 84.19 (− 113.5 to − 54.0) ml/year in the non-responder group. When the 3 patients from the responder 
group in whom sirolimus was started due to chylothorax were excluded, the  FEV1 slope was 28.48 (9.05–47.91) 
ml/year. When using  FEV1 as percentage of predicted (%pred) values, mean (95% CI)  FEV1 slope over 5 years 
was 0.43 (− 0.55 to 1.41) %pred/year in the whole LAM group, 2.17 (1.25 to 3.09) %pred/year in the responder 
group, − 1.78 (− 2.50 to − 1.05) %pred/year in the partial responder group and − 2.96 (− 4.05 to − 1.87) %pred/
year in the non-responder group. Table 3 summarises the differences in  FEV1 at 1 year and 5 years and Fig. 4 
shows the linear prediction of longitudinal changes in  FEV1 (ml).
Eleven patients with angiomyolipoma were treated with sirolimus for at least one year. Table 4 shows angio-
myolipoma sizes before and after 1 year of sirolimus treatment: 10 (91%) patients showed a response to treatment 
and only 1 (9%) had an increase in tumour size. During follow-up, no patient presented symptoms related to 
angiomyolipoma.
Figure 3.  Response to sirolimus after 1 and 5 years of treatment.
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Table 2.  Patient’s characteristics according to sirolimus response at 5 years. IQR interquartile range, SD 
standard deviation.
Response Responders (n = 16) Partial responders (n = 8) Non-responders (n = 3) p value
Age at diagnosis (years), mean (SD) 35 (6) 50 (8) 39 (5)  < 0.01
Age at start of sirolimus (years), mean (SD) 38 (6) 50 (8) 42 (3) 0.001
Pregnancy before diagnosis, n (%) 9 (31) 4 (50) 3 (67) 0.300
Post-menopausal at sirolimus initiation, n (%) 2 (13) 5 (63) 0 (0) 0.017
Pneumothorax, n (%) 10 (63) 3 (38) 2 (67) 0.468
Chylothorax, n (%) 4 (25) 0 (0) 0 (0) 0.199
Pleurodesis, n (%) 8 (50) 2 (25) 1 (33) 0.483
FVC (ml), mean (SD)
before sirolimus 2959 (825) 2854 (521) 3187 (479) 0.794
FEV1 (ml), mean (SD)
before sirolimus 1961 (632) 1980 (602) 1730 (789) 0.831
DLCO (%), mean (SD)
before sirolimus 52 (14) 52 (16) 38 (24) 0.411
Mean sirolimus blood trough levels 8.2 (2.9) 6.6 (2.7) 7.1 (1.1) 0.374
Table 3.  FEV1 response to sirolimus in 27 patients treated with sirolimus for 5 years. Data are shown as Mean 
(95% CI).
All (n = 27) Responders (n = 16) Partial responders (n = 8) Non-responders (n = 3) p value






















































Figure 4.  Linear prediction of longitudinal changes in  FEV1 (ml) and predictive margins with 95% CI using 
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Discussion
There are few data on long-term pulmonary function results in LAM patients receiving sirolimus. The main 
finding from this study was that 59% of sirolimus-treated patients were considered responders because they 
had a sustained spirometric improvement after 5 years of treatment. The MILES trial found that the  FEV1 slope 
in the sirolimus group gained 1 ± 2 ml per month during the first year of  treatment8. Although this difference 
was statistically significant between sirolimus and placebo groups, a substantial number of patients receiving 
sirolimus treatment had a decrease in  FEV1 during this period. One recent Japanese series of 63 patients treated 
with sirolimus for 2 years showed an  FEV1 decline rate of between 0.67 and 2.09 ml per month but did not dif-
ferentiate between responders and non-responders16. One study that reported long-term effects of sirolimus in 12 
patients found differences in  FEV1 before and after treatment of − 55 ± 7 ml and − 5 ± 12 ml per year, respectively, 
with a follow-up time of 4.6 years on  sirolimus9. A Chinese study which evaluated long-term sirolimus effect in 
32 patients also found stabilization of pulmonary function after 4 years of sirolimus  treatment17. It is clear that 
some patients treated with sirolimus do not respond to treatment and continue to lose lung  function18. In the 
present series, 59% of sirolimus-treated patients were considered responders because had a mean  FEV1 slope 
over 5 years of 42 ml/year vs a mean  FEV1 slope of − 54 ml/year in the partial responders vs − 84 ml/year in the 
non-responders. We have also assessed the change of  FEV1% predictive increasing in mean 2.17% in responders 
and dropping 2.96% in non-responders per year. In summary, of those treated for 5-years sirolimus treatment 
led to a clear improvement in lung function in half of the patients and had a modest effect in another 30%. Only 
11% of sirolimus-treated patients had no improvement in  FEV1.
Another relevant aspect is the potential role of sirolimus as a preventive treatment of pleural complications. 
The present study supports the idea that sirolimus may have some preventive effect against pneumothorax and, 
probably, chylous effusions. Intuitively, it could be that chylothorax disappearances after sirolimus treatment 
might be the cause of pulmonary function improvement in those patients with chylothorax. But, chylothorax 
improvement is in fact secondary to sirolimus treatment. This good response of patients with chylothorax to 
sirolimus treatment had also been observed by Takada and  colleagues16.
In the present series, only 9 patients treated with sirolimus were submitted to LT. The role of LT for LAM 
patients has evolved over time. During the 1980s, 1990s and early 2000s, the only choice for LAM patients with 
respiratory failure was LT, and LAM was a rare indication for  LT19. In our series with more than 1100 LTs, LAM 
represents 2.5% of the total LT caseload. There was only one LAM patient who received LT and belong to CC.
The differences between the HSC and the CC, could be explained by several factors. Although the introduc-
tion of sirolimus in the treatment of LAM seems the likely main cause of these differences, other factors such 
as increased knowledge and interest in LAM in recent years, the development of a specialist referral centre, and 
earlier diagnosis with higher functional reserve could explain the better results in the CC cohort. All these factors 
are likely to have influenced the overall improved survival in LAM patients in the last decade and the current per-
ception that LT in LAM will become anecdotal. Perhaps, though, this scenario is somewhat optimistic: we must 
add a note of caution as our data showed that sirolimus had no effect in 11% of patients with LAM at 5-years.
We observed a positive effect in most cases of angiomyolipoma after one year of treatment, but no effect in 
9%. These results are in line with the study published by Bissler et al. that reported no effect in 20% of  cases10. 
Also, we found that more than half of the patients who had a positive response in terms of reduction and stabi-
lization of angiomyolipomas had a positive pulmonary functional response. Bissler and colleagues reported the 
same effect in 7 out of 11 patients who had PFT data at 1 year of sirolimus treatment. Davies et al. also reported, 
in 12 patients, a 50% decrease in angiomyolipoma size without a significant improvement in lung function dur-
ing sirolimus therapy. None of the authors reported any data on a correlation between angiomyolipoma and 
pulmonary function  response10,20.
Table 4.  Angiomyolipomas’ shrinkage rate at 1 year. AML angiomyolipoma. *TSC-LAM.
Patients Number of AML
AML size before sirolimus treatment 
(cm)
AML size after 1-year of sirolimus 
(cm)
FEV1 difference at 1-year of sirolimus 
treatment (ml) Shrinkage rate (%)


















LAM-5 1 0.4 × 0.5 0.4 × 0.5 130 0
LAM-6 2 1 × 1 1 × 1 660 0
LAM-7 1 5.5 × 3.5 4.2 × 2.7 40  − 23
LAM-8 1 0.5 × 0.5 0.5 × 0.5  − 30 0
LAM-9 2 2.6 × 12 × 1
2.6 × 1
2 × 1 140 0
LAM-10 1 2 × 1.6 2 × 1.6 90 0
LAM-11 1 6.6 × 4.5 3.3 × 3.7 20  − 50
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Regarding safety, we recorded side effects in 33% of patients, mainly mild or moderate, and only 1 patient 
discontinued sirolimus due to side effects. Other authors observed the same spectrum of side effects but in 50% to 
59% of  patients16,21. We did not observe any cases of pneumonitis, something that has previously been  described21. 
One of the reasons for these differences could be the retrospective design of our study in contrast with other 
prospective  studies16,21. However, we consider that all serious adverse events were reported and recorded.
The main limitation of the study is its retrospective, single-centre design. The number of LAM patients 
included in the study was conditioned by the rarity of the disease and covers an extended period of 30 years; this 
is a limitation for most LAM studies. The strengths include the homogeneity of the clinical care and criteria, as 
most patients were treated by the same team, who had extensive experience with mTOR inhibitors, LT, and the 
long-term follow-up of sirolimus-treated patients.
In conclusion, sirolimus treatment in LAM has a long-term positive or moderate effect in most patients. LT 
remains the treatment of choice in LAM patients with respiratory failure. Determining the long-term effects of 
sirolimus on survival, the mechanisms that preclude treatment response and identifying potential biomarkers 
are important future priorities.
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